{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "TAZORAC",
      "indication": "1 INDICATIONS AND USAGE TAZORAC \u00ae Cream 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) TAZORAC Cream 0.1% is indicated for the topical treatment of acne vulgaris. ( 1.2 ) 1.1 Plaque Psoriasis TAZORAC \u00ae (tazarotene) Cream, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis. 1.2 Acne Vulgaris TAZORAC (tazarotene) Cream, 0.1% is also indicated for the topical treatment of patients with acne vulgaris.",
      "manufacturer": "Almirall, LLC",
      "splSetId": "021744d1-a6d7-4ad6-99c2-7187c24e64c6"
    },
    {
      "brand": "TAZAROTENE",
      "indication": "1 INDICATIONS AND USAGE \u2022 Tazarotene cream 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) \u2022 Tazarotene cream 0.1% is indicated for the topical treatment of acne vulgaris. ( 1.2 ) 1.1 Plaque Psoriasis Tazarotene cream, 0.1% is indicated for the topical treatment of patients with plaque psoriasis. 1.2 Acne Vulgaris Tazarotene cream, 0.1% is also indicated for the topical treatment of patients with acne vulgaris.",
      "manufacturer": "Fougera Pharmaceuticals Inc.",
      "splSetId": "10ac61b3-cf91-4d83-b253-e9b0b22567ac"
    },
    {
      "brand": "Tazarotene",
      "indication": "1 INDICATIONS AND USAGE Tazarotene cream 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) Tazarotene cream 0.1% is indicated for the topical treatment of acne vulgaris. ( 1.2 ) 1.1 Plaque Psoriasis Tazarotene cream, 0.1% is indicated for the topical treatment of patients with plaque psoriasis. 1.2 Acne Vulgaris Tazarotene cream, 0.1% is also indicated for the topical treatment of patients with acne vulgaris.",
      "manufacturer": "Cosette Pharmaceuticals, Inc.",
      "splSetId": "21b4f33b-a7e6-4653-9cec-b0e0e5797f1a"
    },
    {
      "brand": "Tazarotene",
      "indication": "1 INDICATIONS AND USAGE Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. Tazarotene cream, 0.1% is a retinoid indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper- and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. ( 1 ) Limitations of Use: Does not eliminate or prevent wrinkles or restore more youthful skin. ( 1 ) Does not repair sun damaged skin or reverse photoaging. ( 1 ) Safety and effectiveness for the prevention or treatment of actinic keratoses, skin neoplasms, or lentigo maligna have not been established. ( 1 , 5.4 ) Limitations of Use: Tazarotene cream does not eliminate or prevent wrinkles or restore more youthful skin. Tazarotene cream does not reverse photoaging or repair sun damaged skin; tazarotene cream does not mitigate coarse or deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. The safety and the effectiveness of tazarotene cream for the prevention or treatment of actinic keratoses, skin neoplasms, or lentigo maligna have not been established.",
      "manufacturer": "Taro Pharmaceuticals U.S.A., Inc.",
      "splSetId": "34d79c31-1568-4797-a4f5-31200c7788db"
    },
    {
      "brand": "Tazarotene",
      "indication": "1 INDICATIONS AND USAGE Tazarotene cream 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) Tazarotene cream 0.1% is indicated for the topical treatment of acne vulgaris. ( 1.2 ) 1.1 Plaque Psoriasis Tazarotene cream, 0.1% is indicated for the topical treatment of patients with plaque psoriasis. 1.2 Acne Vulgaris Tazarotene cream, 0.1% is also indicated for the topical treatment of patients with acne vulgaris.",
      "manufacturer": "Taro Pharmaceuticals U.S.A., Inc.",
      "splSetId": "478ff059-9d7b-438e-a64e-c853dfac2872"
    },
    {
      "brand": "Tazorac",
      "indication": "1 INDICATIONS AND USAGE TAZORAC \u00ae Gel, 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement. ( 1.1 ) TAZORAC Gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris. ( 1.2 ) Limitations of Use The safety of TAZORAC Gel use on more than 20% body surface area has not been established. ( 1.3 ) 1.1 Plaque Psoriasis TAZORAC\u00ae (tazarotene) Gel, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement. 1.2 Acne Vulgaris TAZORAC (tazarotene) Gel, 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity. The efficacy of TAZORAC Gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established. 1.3 Limitations of Use The safety of TAZORAC Gel use on more than 20% body surface area has not been established in psoriasis or acne [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )].",
      "manufacturer": "Almirall, LLC",
      "splSetId": "4e4e4b81-420e-4492-8a74-80b692a80057"
    },
    {
      "brand": "TAZORAC",
      "indication": "1 INDICATIONS AND USAGE TAZORAC \u00ae Gel, 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement. ( 1.1 ) TAZORAC Gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris. ( 1.2 ) Limitations of Use The safety of TAZORAC Gel use on more than 20% body surface area has not been established. ( 1.3 ) 1.1 Plaque Psoriasis TAZORAC\u00ae (tazarotene) Gel, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement. 1.2 Acne Vulgaris TAZORAC (tazarotene) Gel, 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity. The efficacy of TAZORAC Gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established. 1.3 Limitations of Use The safety of TAZORAC Gel use on more than 20% body surface area has not been established in psoriasis or acne [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )].",
      "manufacturer": "Allergan, Inc.",
      "splSetId": "75145c21-6ef2-455a-8a67-d48ddd4181a4"
    }
  ],
  "id": "Tazarotene",
  "nciThesaurus": {
    "casRegistry": "118292-40-3",
    "chebiId": "CHEBI:32184",
    "chemicalFormula": "C21H21NO2S",
    "definition": "A synthetic, topical retinoid.  Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene.  In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation.",
    "fdaUniiCode": "81BDR9Y8PS",
    "identifier": "C29487",
    "preferredName": "Tazarotene",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C804"
    ],
    "synonyms": [
      "6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-Pyridinecarboxylic Acid, Ethyl Ester",
      "AGN-190168",
      "Avage",
      "Ethyl 6-(2-(4,4-Dimethylthiochroman-6-yl)ethynyl)nicotinate",
      "TAZAROTENE",
      "Tazarotene",
      "Tazorac",
      "tazarotene"
    ]
  }
}